The FINEARTS-HF trial, which compared Kelendia with placebo when added to standard of care, met its primary endpoint of reducing cardiovascular death and all heart failure events.
Kerendia demonstrates remarkable efficacy in treating heart failure with left ventricular ejection fraction of 40% or higher
Leave a comment
